A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.

Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I
Crit Care Med. 2013 41 (9): 2069-79

PMID: 23979365 · DOI:10.1097/CCM.0b013e31828e9b03

MeSH Terms (17)

Adolescent Adult Aged Aged, 80 and over Disseminated Intravascular Coagulation Double-Blind Method Female Humans Intensive Care Units Male Middle Aged Outcome Assessment, Health Care Placebos Recombinant Proteins Sepsis Thrombomodulin Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: